BRIEF published on 01/15/2025 at 07:35, 1 year 10 months ago GenSight Biologics Reports Long-Term Results for LUMEVOQ® Gene Therapy GenSight Biologics LUMEVOQ® Visual Acuity Leber's Hereditary Optic Neuropathy
PRESS RELEASE published on 01/15/2025 at 07:30, 1 year 10 months ago Inside Information / Other news releases GenSight Biologics announces the publication of 5-year outcomes for patients treated with LUMEVOQ® gene therapy, showing sustained bilateral improvement in visual acuity and favorable safety profile Gene Therapy GenSight Biologics LUMEVOQ Visual Acuity Safety Profile
BRIEF published on 01/13/2025 at 11:31, 1 year 10 months ago Heights Capital Management exceeds 5% stake in GenSight Biologics Capital Increase Shares And Voting Rights GenSight Biologics Heights Capital Management Capital Participation
BRIEF published on 12/24/2024 at 20:51, 1 year 10 months ago GenSight Biologics Secures €1.5 Million Financing from Existing Investors Investors Warrants Financing Gene Therapy GenSight Biologics
PRESS RELEASE published on 12/24/2024 at 20:46, 1 year 10 months ago Inside Information / Other news releases GenSight Biologics announces a c. €1.5 million financing from existing investors through a Reserved Offering to support gene therapy development for retinal diseases and CNS disorders Financing Gene Therapy GenSight Biologics Retinal Diseases Reserved Offering
BRIEF published on 11/13/2024 at 07:35, 2 years ago GenSight Biologics Submits LUMEVOQ® Dossier to ANSM Gene Therapy GenSight Biologics Early Access Program Leber Hereditary Optic Neuropathy Regulatory Submission
PRESS RELEASE published on 11/13/2024 at 07:30, 2 years ago Inside Information / Other news releases GenSight Biologics submits updated LUMEVOQ Dossier to ANSM for early access program restart in France to treat LHON, aiming for first injections in December 2024 GenSight Biologics LHON LUMEVOQ Early Access Program ANSM
BRIEF published on 11/01/2024 at 18:23, 2 years ago GenSight Biologics Secures €2.8 Million Financing Warrants Financing Gene Therapy GenSight Biologics Retinal Diseases
PRESS RELEASE published on 11/01/2024 at 18:18, 2 years ago Inside Information / Other news releases GenSight Biologics announces a €2.8 million financing through a Reserved Offering. Funding to extend cash runway for developing gene therapies. Details on investor support and future plans Investors Financing GenSight Biologics Gene Therapies Reserved Offering
BRIEF published on 10/24/2024 at 21:13, 2 years ago GenSight Biologics Discloses Cash Position, Advances on LUMEVOQ® Treasury Funding LUMEVOQ® ANSM Compassionate Access
Published on 11/20/2026 at 15:00, 1 day 14 hours ago Jaguar Health, Inc. Announces Reverse Stock Split
Published on 11/20/2026 at 14:50, 1 day 14 hours ago Proposed Issue Of Payment-In-Kind Interest Shares Under Convertible Debenture
Published on 11/20/2026 at 14:00, 1 day 15 hours ago Dateline appoints Tony Ferguson as Acting Chairman
Published on 11/20/2026 at 13:30, 1 day 15 hours ago Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
Published on 11/20/2026 at 13:30, 1 day 15 hours ago Alset AI Closes Non-Brokered Private Placement Offering
Published on 11/20/2026 at 23:45, 1 day 5 hours ago APEC CEO Summit 2026 Concludes Successfully in Shenzhen
Published on 11/20/2026 at 21:36, 1 day 7 hours ago EQS-Adhoc: Global Health Care AG: Board of Directors proposes sale of milon stake based on an equity value of EUR 23.3 million – subscription right for all shareholders
Published on 11/20/2026 at 19:26, 1 day 9 hours ago EQS-Adhoc: TAKKT AG: TAKKT revises its 2026 full-year forecast following the cyberattack
Published on 11/20/2026 at 19:03, 1 day 9 hours ago EQS-Adhoc: Allgeier SE confirms rumors regarding sale process for the Evora Group
Published on 11/20/2026 at 18:34, 1 day 10 hours ago Disclosure of transactions in own shares from November 16 to November 20, 2026
Published on 11/20/2026 at 17:35, 1 day 11 hours ago Guillemot Corporation S.A. | Weekly report share buyback from November 16 to November 20, 2026
Published on 11/19/2026 at 19:00, 2 days 10 hours ago MR.BRICOLAGE: OUTLOOK FOR THE 2026 FINANCIAL YEAR
Published on 11/19/2026 at 08:30, 2 days 20 hours ago Data sovereignty: Cegedim opens EB6, a next-generation datacenter for AI and high-density computing